Comparison of immunogenicity and safety of licensed Japanese encephalitis vaccines: A systematic review and network meta-analysis

Vaccine ◽  
2021 ◽  
Author(s):  
Luis Furuya-Kanamori ◽  
Chang Xu ◽  
Suhail A.R. Doi ◽  
Justin Clark ◽  
Kinley Wangdi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Japanese Encephalitis ◽  
Meta Analysis

Vaccination against Japanese encephalitis with IC51: systematic review on immunogenicity, duration of protection and safety

2020 ◽  
Vol 27 (2) ◽  
Author(s):  
Kerstin Kling ◽  
Thomas Harder ◽  
Zane Younger ◽  
Gerd Burchard ◽  
Jonas Schmidt-Chanasit ◽  
...  
Keyword(s):  
Systematic Review ◽  
Japanese Encephalitis ◽  
Meta Analysis ◽  
Age Groups ◽  
Risk Groups ◽  
The Body ◽  
Trial Methodology ◽  
Serious Adverse Events ◽  
Clinical Trial Methodology ◽  
Randomized Studies

Abstract Japanese encephalitis is a disease caused by a flavivirus which is transmitted by mosquitos in endemic countries. Considering the potentially severe outcomes of the disease, vaccination is recommended for those at risk of exposure. During recent years, IC51 (IXIARO®, JESPECT®, JEVAL®) has increasingly been used to protect travellers from Europe and the USA. However, no systematic review exists that summarizes the currently available evidence on the immunogenicity and safety of this vaccine. We conducted a systematic review on the immunogenicity and safety of IC51, using the databases PubMed, MEDLINE, EMBASE and ClinicalTrials.gov (search date: 31 August 2019). Data extracted from included studies were grouped by outcomes and stratified by population and setting. Risk of bias (ROB) was assessed using the RoB 2 tool for randomized controlled trials (RCTs) and ROBINS-I for non-randomized studies. Due to high heterogeneity, meta-analysis was not performed. A total of 32 studies from 16 countries met the inclusion criteria (15 RCTs, 17 non-randomized studies). ROB was serious or high in the majority of studies. Seroprotection rates ranged from 93 to 100% in adults (seven studies) and from 91 to 100% in children (four studies). In the study involving adults aged 64 years and older, seroprotection was 65% with higher rates in persons who were previously vaccinated against tick-borne encephalitis virus. Safety was investigated in 27 studies. Rates of serious adverse events were below 5% in all age groups, with the majority not being causally related to the vaccine. IC51 is a safe vaccine with good seroprotective abilities in persons aged >2 months to <64 years. The body of evidence, however, is weakened by a large amount of heterogeneity in study and clinical trial methodology. Further well-designed RCTs with special risk groups are needed.

Are all vaccines safe for the pregnant traveller? A systematic review and meta-analysis

2019 ◽  
Vol 27 (2) ◽  
Author(s):  
Roni Nasser ◽  
Stav Rakedzon ◽  
Yaakov Dickstein ◽  
Amjad Mousa ◽  
Ido Solt ◽  
...  
Keyword(s):  
Systematic Review ◽  
Adverse Events ◽  
Pregnant Women ◽  
Yellow Fever ◽  
Japanese Encephalitis ◽  
Observational Studies ◽  
Hepatitis A ◽  
Meta Analysis ◽  
Meningococcal Vaccines ◽  
Tick Borne Encephalitis

Abstract Pregnant travellers and their offspring are vulnerable to severe outcomes following a wide range of infections. Vaccine-preventable diseases can have a particularly severe course in pregnant women, but little is known about the safety of travel vaccines in pregnant women. We performed a systematic review of all published literature concerning the safety of vaccines frequently given to travellers such as yellow fever, MMR (mumps, measles and rubella), influenza, Tdap (tetanus, diphtheria and pertussis), meningococcus, hepatitis A and B, rabies, polio, typhoid fever, tick-borne encephalitis and Japanese encephalitis vaccines. We included case series, cohort studies and randomized controlled trials (RCTs). For the meta-analysis, we included only RCTs that compared the administration of a vaccine to placebo or to no vaccine. Outcome measures included severe systemic adverse events, maternal outcomes related to the course of pregnancy, neonatal outcomes and local adverse events. We calculated the risk ratio and its 95% confidence interval as the summary measure. The safety of influenza vaccine is supported by high-quality evidence. For Tdap vaccine, no evidence of any harm was found in the meta-analysis of RCTs. A slight increase in chorioamnionitis rate was reported in 3 out of 12 observational studies. However, this small possible risk is far outweighed by a much larger benefit in terms of infant morbidity and mortality. Meningococcal vaccines are probably safe during pregnancy, as supported by RCTs comparing meningococcal vaccines to other vaccines. Data from observational studies support the safety of hepatitis A, hepatitis B and rabies vaccines, as well as that of the live attenuated yellow fever vaccine. We found little or no data about the safety of polio, typhoid, Japanese encephalitis, tick-borne encephalitis and MMR vaccines during pregnancy.

scholarly journals Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: A systematic review and meta-analysis

2015 ◽  
Vol 11 (6) ◽  
pp. 1418-1425 ◽  
Author(s):  
Shi-Yuan Wang ◽  
Xiao-Hua Cheng ◽  
Jing-Xin Li ◽  
Xi-Yan Li ◽  
Feng-Cai Zhu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Japanese Encephalitis ◽  
Meta Analysis ◽  
Asia Pacific ◽  
Pacific Area

scholarly journals Seroepidemiological Studies on Japanese Encephalitis: A Systematic Review

2021 ◽  
Author(s):  
Nur Suhada Ramli ◽  
Norayuni Mohd Ismail ◽  
Naeemah Zaini ◽  
Firdaus Hayati ◽  
Mohammad Saffree Jeffree ◽  
...  
Keyword(s):  
Systematic Review ◽  
South Korea ◽  
Japanese Encephalitis ◽  
Meta Analysis ◽  
Natural Infection ◽  
Seroprevalence Rate ◽  
Eligibility Criteria ◽  
Age Cohorts ◽  
National Immunisation ◽  
And Control

Background Japanese encephalitis (JE) is one of the major mosquito-borne infectious diseases in the Western Pacific region, accounting for 20-30% of mortality cases. The JE virus (JEV) seroprevalence fluctuations indicate that continuous research is important for prevention and control activities. By mapping JEV seroprevalence by age stratification, the population profile for immunity and susceptibility can be identified to aid in vaccination programme planning. Thus, the aim of this study is to determine the trend of age-specific JEV seroprevalence. Method Systematic search was conducted on all studies conducted on JEV seroprevalence between the years 2010 until 2019. The two search engines used were PubMed and Web of Science. Eligible criteria were set and articles were screened according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines. Three investigators cross-checked all articles assigned. Data were extracted into Excel sheet and results were tabulated in tables and graphs accordingly. Result Four studies from four countries (Taiwan, Sri Lanka, South Korea, India) met the eligibility criteria. The papers show an increasing trend of JEV seropositivity in all countries as their populations reach older age cohorts. Nonetheless, there were slight downtrend notches seen among young adults in Taiwan and India before increasing again after reaching more mature ages. South Korea has the highest seroprevalence rate (97.8% to 98.3%) among the compared countries; this is most likely because it was the earliest to introduce the JEV vaccine in 1967 which was later made mandatory in early 1980s, while India has the lowest seroprevalence rate (12.9% to 18.1%). Among the old-vaccination-naïve population, seropositivity is commonly derived from natural infection. Conclusion Decreases in reported JE cases are mainly due to immunisation. As JEV is expected to remain in nature and the zoonotic chains, the risk of infection will persist. Hence, it is important to apply JEV vaccination protocols in national immunisation programmes with priority given to those at the young childhood stages.

The effects of low-ratio n-6/n-3 PUFA on biomarkers of inflammation: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Yali Wei ◽  
Yan Meng ◽  
Na Li ◽  
Qian Wang ◽  
Liyong Chen
Keyword(s):  
Systematic Review ◽  
Fatty Acid ◽  
Polyunsaturated Fatty Acid ◽  
Meta Analysis ◽  
Chain Polyunsaturated Fatty Acid ◽  
Inflammation Markers ◽  
Pufa Supplementation ◽  
Long Chain

The purpose of the systematic review and meta-analysis was to determine if low-ratio n-6/n-3 long-chain polyunsaturated fatty acid (PUFA) supplementation affects serum inflammation markers based on current studies.

The association between dietary inflammatory index and risk of central obesity in adults: An updated systematic review and meta-analysis

2020 ◽  
Vol 90 (5-6) ◽  
pp. 535-552 ◽  
Author(s):  
Mahdieh Abbasalizad Farhangi ◽  
Mahdi Vajdi
Keyword(s):  
Systematic Review ◽  
Observational Studies ◽  
Central Obesity ◽  
Assessment Tool ◽  
Weighted Mean Difference ◽  
Meta Analysis ◽  
Dietary Factors ◽  
Cross Sectional ◽  
Inflammatory Status ◽  
Obesity Indices

Abstract. Backgrounds: Central obesity, as a pivotal component of metabolic syndrome is associated with numerous co-morbidities. Dietary factors influence central obesity by increased inflammatory status. However, recent studies didn’t evaluate the association between central obesity and dietary inflammation index (DII®) that give score to dietary factors according to their inflammatory potential. In the current systematic review and meta-analysis, we summarized the studies that investigated the association between DII® with central obesity indices in the general populations. Methods: In a systematic search from PubMed, SCOPUS, Web of Sciences and Cochrane electronic databases, we collected relevant studies written in English and published until 30 October 2019. The population of included studies were apparently healthy subjects or individuals with obesity or obesity-related diseases. Observational studies that evaluated the association between DII® and indices of central obesity including WC or WHR were included. Results: Totally thirty-two studies were included; thirty studies were cross-sectional and two were cohort studies with 103071 participants. Meta-analysis of observational studies showed that higher DII® scores were associated with 1.81 cm increase in WC (Pooled weighted mean difference (WMD) = 1.813; CI: 0.785–2.841; p = 0.001). Also, a non-significant increase in the odds of having higher WC (OR = 1.162; CI: 0.95–1.43; p = 0.154) in the highest DII category was also observed. In subgroup analysis, the continent, dietary assessment tool and gender were the heterogeneity sources. Conclusion: The findings proposed that adherence to diets with high DII® scores was associated with increased WC. Further studies with interventional designs are necessary to elucidate the causality inference between DII® and central obesity indices.

Sign in / Sign up

Export Citation Format

Share Document